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Summary 
Objective: Several reported studies suggest hat repeated intra-articular injections of hyaluronan result in sustained 
relief from pain and functional disability in patients with knee osteoarthritis. Several in vivo data suggest that 
hyaluronan might have a beneficial structural effect in osteoarthritis. The objective of the study was to evaluate the 
potential structure-modifying effects of Hyalgan (50(~730 kDa molecular weight), a highly-purified sodium hyaluronate. 
Design: Patients with painful knee osteoarthritis (ACR criteria) were enrolled in a prospective, controlled study of 
1-year duration. After randomization, either conventional therapy or three cycles (every 3 months) of three 
intra-articular injections of Hyalgan (once a week during 2 weeks) were given. Clinical outcome was added using pain 
visual analog score (VAS), functional impairment: Lequesne's index, quality of life: arthritis impact measurement scale 
(AIMS2) and structural outcome using X-rays: joint space narrowing and arthroscopy: global assessment using VAS, 
SFA scoring and grading systems. 
Results: Of the 39 recruited patients, 36 completed the l-year trial (19 in the Hyalgan group and 17 in the control 
group). There was no difference between groups at entry. Between-group comparison for changes in clinical parameters 
reached statistical significance for the quality of life index (AIMS2:-0.4 ± 0.7 vs +0.2 _+ 0.9 in the Hyalgan and control 
groups respectively, P < 0.05). Deterioration in the structural parameters was less in the Hyalgan group, with a 
statistically significant difference for two of the three evaluated parameters (overall assessment of chondropathy: 
+5.1 ± 12.7 vs 16.7 ± 18.3, P-- 0.016; SFA scoring system: +3.7 _+ 7.3 vs +9.0 ± 11.5, P= 0.05) in the Hyalgan and control 
groups, respectively. 
Conclusions: This study supports existing data concerning the favorable symptomatic effect of intra-articular 
injections of Hyalgan in osteoarthritis of the knee and suggests that repeated intra-articular injections of Hyalgan 
might delay the structural progression of the disease. Other studies are required to confirm these results and to 
determine the long-term monitoring of osteoarthritic patients using such local therapy. 
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Introduction 
DRUGS considered to be act ive in the t reatment  of 
osteoarthr i t i s  may be classif ied as symptomat ic  
and/or  s t ructure-modi fy ing agents  [1, 2]. Monitor-  
ing the effects of symptomat ic  agents  in pat ients  
suffer ing f rom osteoarthr i t i s  of the knee is usual ly  
based on cl inical  measurements  of changes in pa in  
and/or  funct ion [3, 4]. Such outcome measures  may 
be inf luenced by effective symptomat ic  agents  
whatever  their  mechan ism of act ion [5, 6] but  do 
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not  permit  the eva luat ion  of the potent ia l  of  these 
drugs to act d i rect ly  on the cart i lage.  The 
In ternat iona l  League of Assoc iat ion for Rheuma-  
to logy has defined chondroprotect ive  agents  as 
agents  capable  of prevent ing,  delaying, or even 
revers ing cart i lage lesions due to os teoar thr i t i s  in 
humans.  However ,  the outcome measures  for 
cart i lage lesions are not  c lear ly establ ished.  
Rad iograph ic  assessment  of affected knees  has 
been reported as an object ive s tandard  for 
long-term eva luat ion  of knee osteoar thr i t i s  [7, 8] 
but  is sti l l  ta inted by false-posit ive and false- 
negat ive  fiffdings [9]. 
I t  was reported in a previous study [10] that  
(1) ar throscop ic  eva luat ion  of ar t i cu lar  car t i lage 
of the knee was not  simple, but  was feasible and 
wel l - to lerated as an outpat ient  procedure  under  
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local anesthesia with a small arthroscope; (2) the 
quantification of chondropathic severity was 
feasible using either the physician's overall 
assessment with a 100mm visual analog scale 
(VAS) or the scoring systems proposed by the 
French Society of Arthroscopy which are com- 
posite indices taking into account he three main 
characteristics of chondropathy, i.e., localization, 
depth and size [11, 12]. Previous studies have 
shown that this method fulfills some of the guide- 
lines proposed for outcome measures: validity, 
reproducibility and clinical relevance [10-12]. 
Hyaluronan (hyaluronic acid) forms the central 
axis of the various proteoglycan aggregates 
necessary for the functional integrity of cartilage 
and other extracellular matrices [13]. Hyaluronic 
acid is responsible for the unique viscoelastic 
properties of the synovial fluid [14-16] and is 
thought o play an important role in biological 
activities as diverse as cell proliferation and 
activation [17-20]. Its clinical use was suggested 
by the finding that hyaluronic acid was reduced 
in concentration and in chain length in the 
synovial fluids of arthritic patients [14]. The 
term 'viscosupplementation' has been used to 
describe the effects of high-molecular-weight 
hyaluronan [21]. However, this concept is based 
only on the mechanical properties of the molecule 
while there is a considerable body of evidence 
that the therapeutic efficacy of hyaluronan is 
due to a combination of both physicochemical 
and pharmacological properties [22]. 
Several studies with various preparations of 
hyaluronan of different molecular weights have 
been conducted [23-25 and reviewed in 26], and 
there has been a broad consensus in the studies 
published that this treatment is well-tolerated and 
results in sustained relief of pain and functional 
disability of patients suffering from knee osteo- 
arthritis. This clinical improvement is usually 
observed after three to five injections performed at 
1-week intervals. Moreover, a carry-over effect for 
at least 3 months after discontinuation has been 
suggested. 
Animal model studies suggest hat hyaluronan 
affects the progression of chondral lesions [27, 28]. 
To our knowledge, no data have been published in 
the literature suggesting that intra-articular 
injections of hyaluronic acid might interfere with 
the natural course of the cartilage lesions observed 
in knee osteoarthritis n humans. Therefore, it 
seemed interesting to conduct he following pilot 
study in order to evaluate, by arthroscopy, the 
effects of repeated intra-articular injections of 
hyaluronan. 
Pat ients  and  Methods  
PAT IENTS 
Patients suffering from knee osteoarthritis 
fulfilling the American College of Rheumatology 
criteria [29] were enrolled in the study. Other 
inclusion criteria were the following: 
(1) primary osteoarthritis as defined by the 
American College of Rheumatology [29]; 
(2) clinical involvement of the medial compart- 
ment (pain localized at the medial part of the 
knee); 
(3) active disease (pain and disability) justify- 
ing local therapy (lavage) at entry (based on the 
opinion of the investigator); 
(4) absence of contraindication of arthroscopy 
(anti-coagulant therapy, cutaneous lesion of the 
knee, allergy to lidocaine); 
(5) absence of advanced isease defined by a 
radiological grade IV according to  the classifi- 
cation proposed by Kellgren and Lawrence [30]; 
(6) presence of chondropathy o~the  medial 
compartment at arthroscopy defined by the 
presence of chondropathy at least grade II 
according to the classification proposed by Beguin 
and Locker [31] and observed on at least 10% of the 
evaluated surface. 
Patients were not included in the study if (1) any 
intra-articular surgery was performed uring the 
past 5 years (including any arthroscopic pro- 
cedure). (2) Any intra-articular treatment was 
prescribed i.e., lavage, intra-articular injection of 
corticosteroids during the past 3 months. Any 
concurrent symptomatic treatment, i.e., anal- 
gesics, nonsteroidal anti-inflammatory drugs 
(NSAIDs), physiotherapy had to be stable for at 
least 1 month before the study. 
STUDY MEDICAT ION 
Hyalgan ~), supplied by Fidia S.p.A., is a 
concentrated (20 mg]2 ml) solution of 500-730 kDa 
molecular weight, highly-purified sodium 
hyaluronate extracted from rooster combs. 
STUDY DES IGN 
The study was a single-center, prospective, 
randomized, controlled study of 1-year duration 
approved by the ethics committee of Cochin 
Hospital, Paris. All patients underwent knee 
arthroscopy during which lavage (2 1 saline serum) 
was performed. After the arthroscopy procedure, 
and after written informed consent was obtained, 
the patients entered one of the two study groups 
Osteoarthr i t i s  and Carti lage Vol. 5 No. 3 155 
according to a randomization scheme. The control 
group did not receive any intra-articular injection 
of hyaluronan during the 1 year of the study. The 
treated group received three intra-articular injec- 
tions of Hyalgan once a week during 2 weeks (three 
injections) every 3 months, for a total of nine 
injections. The first injection was performed 1 
month after arthroscopy and the last 3 months 
before the final visit. Before each injection, any 
synovial fluid was aspirated. 
Moreover, joint space width, was evaluated by the 
interbone distance betweefi the medial femoral 
condyle and the tibial plateau at the narrowest 
point in millimeters [8]. The paired radiographs of 
each patient at entry and after I year were 
analyzed by a single investigator (V.L.) using a 
blind procedure in which the investigator was 
unaware of patient identity and the chronology of 
the radiographs. 
DATA COLLECTION 
Clinical characteristics 
Demographic data and parameters of osteoar- 
thritis were recorded at entry for each patient, and 
included age, sex, body mass index, date of onset 
of osteoarthritis, and number of joints affected by 
osteoarthritis. Moreover; clinical, radiological and 
arthroscopical variables were collected at entry 
and after 1 year. 
Clinical activity of osteoarthritis was assessed 
using the following variables: (1) global pain in 
the previous 48 h evaluated on a 100 mm length 
VAS and (2) functional disability, evaluated via (a) 
Lequesne's functional index [32], which consists of 
10 questions regarding the presence of pain or 
disability, and (b) the French version of the revised 
arthritis impact measurement scale (AIMS2) [33]. 
These clinical parameters were collected by a 
physician who was aware of the patient group, i.e., 
using a non-blinded procedure. Moreover during 
the study, any requirement for concomitant 
therapy, e.g., analgesics, NSAID was recorded. The 
amount of this rescue treatment was calculated 
using the  following methods: (1) an equivalent 
NSAID score, previously reported [34], in order to 
calculate a mean, daily NSAID score. For example, 
a patient aking 100 mg indomethacin daily has a 
score of 10, which is the same score if he/she takes 
150mg diclofenac or 20mg piroxicam, (2) an 
equivalent analgesic score defined by the number 
of pills taken daily by the patient considering that 
one pill of paracetamol is equivalent to one pill of 
dextropropoxyphene. 
Radiological variables 
Radiological evaluation consisted of antero- 
posterior weight-bearing knee X-rays. The struc- 
rural severity of osteoarthritis was determined by 
evaluating the joint space narrowing according to 
a seven-grade scale, previously reported [35]. 
Arthroscopy 
Arthroscopy of the knee was performed under 
local anesthesia, without tourniquet hemostasis, 
with a 2.7ram Storz arthroscope (Storz, Paris, 
France) having a 30 ° fore oblique lens, using the 
inferolateral approach. Each arthroscopy was 
recorded on a ~ inch U-MATIC video-cassette 
(Sony, Paris, France). All the videotapes were 
analyzed by a single investigator (X.A.) using a 
blinded procedure in which the investigator was 
unaware of patient identity and chronology. 
Three scoring methods were used: the overall 
assessment of the. investigator, the revised SFA 
scoring and the SFA grading systems [10=12]. The 
overall assessment of chondropathy was evalu- 
ated using a VAS 100 mm in length, in which 0 
indicates the absence of chondropathy and 100 the 
most severe chondropathy. In the second and 
third methods, i.e., the SFA systems for scoring 
and grading chondropathy [11, 12], the first step is 
recording, on an articular diagram of the knee, 
the observed chondropathies with their main 
baseline parameters: (1) localization: medial femur 
and medial tibia, lateral femur and lateral tibia, 
patella and trochlea; (2) grade based on the 
classification of chondropathy proposed by Be- 
guin and Locker [31] in which grade 0 indicates 
normal cartilage, grade I swelling and/or soften- 
ing, grade II superficial fibrillation, grade III deep 
fibrillation, and grade IV exposure of subchondral 
bone; and (3) size from 0-100% of the involved 
articular surface. Size of lesions is estimated by 
the investigator as a percentage of the whole 
a~icular  surface and is reported on a special form 
[10-12]. 
The revised SFA scoring is a continuous 
variable, between 0 and 100, obtained as follows 
[10]: Revised SFA scoring = surface (%) of grade I
lesions x 0.14 + surface (%) of grade II lesions x 
0.34+surface (%) of grade III lesions x 0.65 + 
surface (%) of grade IV lesions x 1.00. 
The SFA grading is an ordinal variable 
including four grades for the medial, compartment 
[12]. 
156 Listrat et al. :  Hyaluronan in osteoarthrit is  of the knee 
Table I 
Baseline characteristics of the 39 patients uffering from knee osteoarthritis enrolled 
in the study 
Treatment group 
Hyaluronan Control 
Characteristics N= 20 N= 19 P-value* 
Demographic data 
Age (years) (mean, S.D.) 60 ± 7 64 ± 8 NS 
Sex (F/M) 11/9 15/4 NS 
Body mass index (kg/m 2) (mean, S.D.) 27.5 ± 3.8 26.6 ± 3.6 NS 
OA characteristics 
Disease duration (years) 4 2 NS 
(man, S.D., range) (0-26) (0-15) 
Synovial fluid effusion (yes/no) 10/20 10/19 NS 
Number of joints effected by OA 2.6 ± 1.7 2.6 ± 1.2 NS 
(mean, S.D., range) (1--6) (1-5) 
Concomitant NSAID therapy 
during the previous 6 months 
(number of patients) 11 11 NS 
*Statistical significance determined by the nonparametric Mann-Whitney U test 
for the quantitative variables and by the Chi-square test for the qualitative 
variables. NS = not significant. 
Statistical analysis 
Statist ical  analyses were performed to compare 
by t reatment  group the basel ine character ist ics  of 
pat ients and the changes which occurred in the 
clinical, radiological  and arthroscopical  var iables 
dur ing the study. For  the cont inuous efficacy 
parameters,  the analysis of covar iance (ANCOVA) 
using the corresponding basel ine (week 0) assess- 
ment as the covar iate was performed. Categor ical  
variables were analyzed by chi-square test. All 
statist ical tests for the efficacy variables were 
performed two-sided with a level of signif icance 
= 0.05. 
Arthroscopic parameters  have been chosen as 
the apriori  pr imary efficacy variables. However,  at 
the t ime the protocol  was designed, no part icu lar  
scale had been chosen. In this manuscr ipt ,  we 
report  the stat ist ical  analyses concern ing the three 
arthroscopic  parameters,  i.e., the overal l  assess- 
ment of chondropathy using a 100 mm length VAS, 
the SFA scoring system, the SFA grading system. 
Some addit ional  analyses were performed on the 
effect of concomitant  herapy.  NSAID t reatment  
could potent ia l ly  interact  with progression of the 
structura l  disease [35] and NSAID intake might 
depend on the efficacy of the study t reatment  (i.e., 
the h igher  the t reatment  effect, the lower the 
expected NSAID intake). Due to the lack of 
independence between the effect of the t reatment  
and the need for concomitant  reatments,  only 
exploratory analyses were carr ied out. The aims of 
these analyses were to study the main effect of 
NSAID intake on outcome and the effect of the 
interact ion between this var iable and t reatment  on 
outcome. 
Table II 
Symptomatic severity of knee osteoarthritis by treatment groups in the 36 patients who completed the 1 year study 
Entry visit Final visit Difference from baseline 
Hyaluronan Control Hyaluronan Control Hyaluronan Control 
Clinical variables N= 19 N= 17 N= 19 N= 17 N= 19 N= 17 P-value* 
Pain 
(VAS, mm) 49.2 ± 20.1 52.1 ± 16.8 32.4 ± 25.5 46.8 ± 27.7 -16.8 ± 23.9 -5.2 ± 36.6 0.18" 
Functional impairement 
Lequesne's index 8.9 ± 4.1 9.4 ± 3.5 7.2 ±_ 4.8 8.1 ± 4.1 -1.7 + 2.9 -1.4 ± 5.9 0.66* 
Quality of life 
AIMS2 
(total of 12 items) 2.6 ± 1.3 2.2 ± 0.7 2.2 ± 1.3 2.4 ± 1.1 -0.42 _+ 0.67 +0.18 ± 0.88 0.047* 
*ANCOVA analysis. 
Osteoar thr i t i s  and  Car t i lage  Vo l .  5 No .  3 157  
oO 
2 
b0 
~Z 
o, 
.~ o ~ 
0~.~ 
• 0 
28 
N 
.S 
¢q O'~ ,,,,-I LO LO 
co oo  o. 
"H-  
o'9 Iz'o 
~_~ I-4 
~ ~ 4-1 +1 +1 
~5og 
I 
oo  
O 
I 
4-+ 
+1 4-1 
o ~ ~ ÷ 1  +1+1 
~ ~ + 1  +1+1 
~ o ~  +1 +1+1 
I -0~0 
r~ 
V V VI VI ~ ~ ~ .~ 
-o ~ .~-o  ~ .~ o ~ ~ ~ ~ 
V AI AI A A A I '8~ ~ < ~ ~ ' ' - D ~ U > ~  ~ 
.~ r.D 
> 
% -< 
d 
o 
.<~,~ 
g ~g 
.~.~ 
• "~ +. -  . .M-  
158 Listrat et al.: Hyaluronan in osteoarthrit is  of the knee 
Resu l t s  
PATIENTS AND STUDY COURSE 
The baseline characteristics of the 39 patients 
enrolled in the study are summarized in Table I 
and the parameters evaluating the symptomatic 
severity and/or the structural severity of osteo- 
arthritis using clinical, radiological and arthro- 
scopical parameters are summarized in Tables II 
and III. 
At entry, there was no statistically significant 
difference between the two studied groups with 
regard to clinical and radiological variables (see 
Tables I and II). However, at arthroscopy, there 
was a trend in favor of more severe disease in the 
control group which was close to statistical 
significance for the variable SFA scoring (P-value 
of 0.058 when using ANOVA analysis). 
Three patients withdrew from the study during 
the 1 year of follow up: one in the hyaluronan 
group (the patient refused to continue the 
treatment due to lack of pain) and two in the 
control group [one because of moving, one because 
of surgery of the evaluated knee (osteotomy)]. 
Therefore, 36 patients completed the 1 year of the 
study. 
EFFICACY 
Clinical parameters 
Improvement was observed in both groups for 
pain and functional impairment but the differences 
between groups did not reach statistical signifi- 
cance (see Table II). A statistically significant 
difference between the two groups in favor of 
Hyalgan was found in the quality of life 
assessment. Moreover, 30% (six of 20) and 68.4% 
(13 of 19) in Hyalgan and control groups, 
respectively, received a NSAID during the study 
with the difference between groups being statisti- 
cally significant (P = 0.016). The mean daily intake 
was 0.65 + 2.17 and 2.77 + 3.56 in the Hyalgan and 
the control group, respectively, (P=0.044). A 
nonstatistically significant trend in favor of a more 
important analgesic rescue in the control group 
was observed. The paracetamol mean daily intake 
was 0.22 + 0.41 and 0.49 _+ 1.01 in the hyaluronan 
and control group, respectively. 
Structural parameters 
The changes in severity of chondropathy 
evaluated by both X-rays and arthroscopy are 
summarized in Table III. The changes observed in 
structural variables indicate deterioration i both 
groups but to a lower extent in the hyaluronan 
group. For the arthroscopic evaluation, the 
between-groups difference for the SFA scoring 
system and the overall assessment using the VAS 
were statistically significant in favor of Hyalgan, 
and this difference was close to statistical 
significance for the SFA grading system (P = 0.052). 
Evaluation of joint space narrowing and joint 
space width by radiography showed that the 
between-group differences for these parame~ters did 
not reach statistical significance although deterio- 
ration was less in the Hyalgan group. 
The imbalance in the concomitant therapies 
prompted a post-hoc exploratory analysis in order 
to clarify the possible influence of NSAID intake 
on the between-treatments difference. Results of 
simple regression analysis on the SFA score, 
including the treatment and the NSAID consump- 
tion as main effects, and the treatment by NSAID 
interaction effect, showed that the effect of the 
treatment was still statistically significant, and 
neither the NSAID effect or the interaction effect 
was statistically significant. 
ACCEPTABIL ITY 
One patient in the hyaluronan group refused to 
continue the course of intra-articular injections 
because he was free from pain. Moreover, eight 
out of the 20 hyaluronan treated patients (40%) 
reported pain during or immediately after the 
injection for at least one of the nine injections for 
a total of 17 events (180 hyaluronan i jections were 
performed uring the study). In all cases, pain was 
limited to the moment of injection or lasted for a 
few minutes after the injection. No acute hy- 
darthrodial f are of osteoarthritis occurred uring 
the study. 
Discuss ion  
This study supports existing data concerning the 
beneficial symptomatic effects of intra-articular 
injections of hyaluronan in osteoarthritis of the 
knee; and suggests that repeated intra-articular 
injections of hyaluronan might delay structural 
progression of the disease. It also suggests that 
arthroscopy might be able to identify chondro- 
modulating agents; and confirms the feasibility of 
using arthroscopy as an outcome measure of knee 
osteoarthritis. 
Arthroscopy, even simplified, can be considered 
an aggressive method. However, in this study, the 
high percentage (36 out of 39: 92%) of patients 
completing the trial may be considered an 
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argument favoring the good acceptability of this 
technique. 
The results (~btained in this study suggest hat 
this technique is capable of demonstrating statisti- 
cally significant changes in chondropathy in a 
relatively low number of patients (N= = 17) and 
over a 1-year period. Sensitivity to change is one 
of the major characteristics of an outcome 
variable. The results obtained in this study suggest 
that arthroscopic parameters are more sensitive 
than radiological parameters to evaluate the 
changes in structural damage observed in osteo- 
arthritis. 
Although this was not its primary objective, this 
study confirms the beneficial clinical effects of 
intra-articular injections of hyaluronan in knee 
osteoarthritis. However, the study design (open 
procedure to collect the clinical parameters, 
systematic articular lavage in all patients at entry) 
may have influenced the final results. 
The choice of the number of injections within 
each course (three) and the interval between each 
course (3 months) was based on data previously 
reported in different clinical studies suggesting 
that at least three injections (once a week during 
2 weeks) are necessary to improve the clinical 
manifestations of osteoarthritis, and that this 
improvement persists several months after cessa- 
tion of treatment [23-35 and reviewed in 26]. 
It should be noted that the intra-articular 
injections were performed in the hyaluronan 
treatment group even though the patients were 
painless. The acceptability of this procedure 
appeared good as only one patient refused to 
continue the injections because he was free from 
pain. 
Comparison of the changes in severity of 
chondropathy by treatment group during the 1 
year of the study suggests that repeated intra-artic- 
ular injections might delay cartilage lesions due to 
osteoarthritis n humans. Although these results 
have been observed using rigorous methodology, a 
number of aspects must be considered before 
drawing definite conclusions: (1) the imbalance in 
the severity of chondropathy observed at entry; 
(2) the small number of evaluated patients; (3) the 
imbalance in the amount of rescue treatment. For 
example, one can argue that the progression of the 
disease is related to its severity at entry and/or 
that NSAID intake might have a deleterious 
structural effect in osteoarthritis, as has been 
recently suggested [35]. We conducted various 
statistical analyses in order to take into account 
the imbalance in both the severity of chondropathy 
and the amount of rescue treatment in the 
interpretation of the results. The results obtained 
suggest hat in this study NSAID intake alone 
might not represent an explanation for the level of 
cartilage deterioration after I year of study. 
However, the possible role of other patient 
conditions and the suggested effect of the 
treatment in reducing access to concomitant 
therapies impose cautious consideration of this 
result. A direct answer concerning the Possible 
effect of the NSAID alone, or in association with 
other treatments can only be provided by another, 
randomized factorial study where the two exper- 
imental factors (NSAID and other treatments) and 
their combinations are compared. 
Moreover, these results were obtained in a very 
small subgroup of patients. This small sample size 
cannot exclude that the results obtained are due to 
chance alone. The particular characteristics of the 
recruited patients preclude any extrapolation of 
the results to the general population of patients 
with knee osteoarthritis. 
In case of a real effect of hyaluronan intra- 
articular injections on structural damage, it might 
be of interest to evaluate different schedules of 
administration. In this study, we used a 3 month 
repetition of cycles of three intra-articular 
hyaluronan injections to severely symptomatic 
patients. It might be interesting to evaluate the 
effects of repetition of injection cycles performed 
only in case of a clinical flare of the disease. 
In the light of these considerations, further 
studies are required in order to confirm our results 
and to evaluate long-term monitoring of osteo- 
arthritis patients using such local (intra-articular) 
therapy. 
References  
1. Lequesne M, Brandt K, Bellamy N, Moskowitz R, 
Menkes CJ, Pelletier JP, Altman R. Guidelines for 
testing slow acting drugs in osteoarthritis. J 
Rheumatol 1994;21(Suppl. 41):65 71. 
2. Group for the REspect of Ethics and Excellence in 
Science (GREES): osteoarthritis ection. Rec- 
ommendations forthe registration ofdrugs used in 
.the treatment of osteoarthritis. Ann Rheum Dis 
1996;55:552-7. 
3. Paulus HE, Bulpitt KJ. Clinical trials of osteoar- 
thritis therapeies. Br J Rheumatol 1993;32:529-31. 
4. Rosenbloom D, Brooks P, Bellamy N, Buchanan W. 
Clinical trials in the rheumatic diseases, Praeger 
Ed., 1 vol., New York. 1985;19-63. 
5. Dieppe P, Cushnaghan J, Jasani MK, McCrae F, 
Watt I. ~A two-year placebo-controlled trial of 
non-steroidal nti-inflammatory therapy in osteo- 
arthritis of the knee joint. Br J Rheumatol 
1993;32:595-600. 
6. Onghena P, Van Houdenhove B. Antidepressant- 
induced analgesia in chronic non-malignant pain: 
160 Listrat et  a l . :  Hyaluronan in osteoarthr i t i s  of  the knee 
a meta-analysis of 39 placebo-controlled studies. 
Pain 1992;49:205-19. 
7. Altman RD, Fries JF, Bloch DA, Carstens J, Cooke 
TD, Genant H, Gofton F, Groth H, McShane DJ, 
Murphy WA, Sharp JT, Spitz P, Williams C, Wolfe 
F. Radiographic ass~essment of progression in 
osteoarthritis. Arthritis Rheum 1987;30:1214-25. 
8. Ravaud P, Giraudeau B, Auteley GR, Chastang C, 
Poiraudeau S, Ayral X,Dougados M. Radiographic 
assessment of knee osteoarthritis: reproducibility 
and sensitivity to change. J Rheumatol 
1996;23:1756-64. 
9. Fife RS, Brandt KD, Braunstein EM, Katz BP, 
Shelbourne KD, Kalasinski LA, Ryan S. Relation- 
ship between arthroscopic evidence of cartilage 
damage and radiographic evidence of joint pace 
narrowing in early osteoarthritis of the knee. 
Arthritis Rheum 1991;34:377-82. 
10. Ayral X, Dougados M, Listrat V, Bonvarlet JP ,  
Simonnet J, Poiraudeau S, Amor B. Chondroscopy: 
a new method for scoring chondropathy. Semin 
Arthritis Rheum 1993;22:289-97. 
11. Dougados M, Ayral X, Listrat V, Gueguen A, 
Bahuaud J, Beaufils P, Beguin JA, Bonvarlet JP, 
Boyer T, Coudane H, Delaunay C, Dorfmann H, 
Dubos JP, Frank A, Kempf JF, Locker B, Prudhon 
JL, Thiery J. The SFA system for assessing 
articular cartilage lesions at arthroscopy of the 
knee. Arthroscopy 1994;10:69-77. 
12. Ayral X, Gueguen A, Listrat V, Bahuaud J, Beaufils 
P, Beguin J, Bonvarlet JP, Boyer T, Coudane H, 
Delaunay C, Dorfmann H, Dubos JP, Frank A, 
Kempf JF, Locker B, Prudhon JL, Thiery J, 
Dougados M. Simplified arthroscopy scoring 
system for chondropathy of the knee (revised SFA 
score)*. Rev Rhum Engl Ed 1994;61:88-90. 
13. Heinegard D, Oldberg A. Structure and biology 
of cartilage and bone matrix non collagenous 
macromolecules. FASEB J 1989;3:2042-51. 
14. Balazs EA, Watson D, Duff IF, Roseman S. 
Hyaluronic acid in synovial fluid. 1. Molecular 
parameters of hyaluronic acid in normal and 
arthritic human fluids. Arthritis Rheum 
1967;10:357-76. 
15. Balazs EA, Gibbs DS. The rheological properties and 
biological function of hyaluronic acid. In: Balasz 
EA Ed. Chemistry and molecular biology of the 
intercellular matrix. New York: Academic Press, 
1970;1241-54. 
16. Balazs EA. Physical properties of synovial fluid. In: 
Helfet A, Ed. Disorders of the knee. Philadelphia: 
Lippincot Co 1974;63-73. 
17. Goldberg RL, Toole BP. Hyaluronate inhibition of 
cell proliferation. Arthritis Rheum 1987;30:769-78. 
18. Hakansson L, Hallgren R, Venge P. Regulation of 
granulocyte function by hyaluronic acid. In vitro 
and in vivo effects of phacotysosis, locomotion, 
and metabolism. J Clin Invest 1980;66:298-305. 
19. Anastassiades T, Robertson W. Modulation of 
mitogen-dependent lymphocyte stimulation by 
hyaluronic acid. J Rheumatol 1984;11:729-34. 
20 Forrester JV, Balazs EA. Inhibition of phacocytosis 
by high molecular weight hyaluronate. Immu- 
nology 1980;40:435-46. 
21. Peyron JG. A new approach to the treatment of 
osteoarthritis: viscosupplementation. Osteoar- 
thritis Cart 1993;1:85-7. 
22. Ghosh P. The role of hyaluronic acid (hyaluronan) 
in health and disease: interactions with cells, 
cartilage and components of synovial fluid. Clin 
Exp Rheumatol 1994;12:75-82. 
23. Weiss C, Balazs EA, St Onge R, Denlinger JL. 
Clinical studies of the intra-articular injection of 
Healon ® (sodium hyaluronate) in the treatment of 
osteoarthritis of human knees. Semin Arthritis 
Rheum 1981; 11(1 Suppl. 1): 143-144. 
24. Pulh W, Bernau A, Greiling H, Kopcke W, 
Pforringer W, Steck KJ, Zacher J, Scharf HP. 
Intra-articular sodium hyaluronate in osteoar- 
thritis of the knee: a multicentre, double-blind 
study. 0steoarthritis Cart 1993;1;233-241. 
25. Adams ME, Atkinson MH, Lussier AJ, Schultz 
JI, Siminovitch KA, Wade JP, Zummer M. The role 
of viscosupplementation with hylan G.F. 20 
(Synvisc) in the treatment of osteoarthritis of 
the knee: a Canadian multicentre trial compar- 
ing hylan F-F 20 alone, hylan G-F 20 with NSAIDs 
and NSAIDs alone. Osteoarthritis Cart 1995;3: 
213-26. 
26. Maheu E. Hyaluronan in knee osteoarthritis: a
review of the clinical tr ials with Hyalgan ~. Eur J 
Rheumatol Inflam 1995;15:1724. 
27. Abatangelo G, Botti P, Del Bue M, Gei G, Samson 
J, Cortivo R, De Galate A, ~arte l l i  M. Intra- 
articular sodium hyaluronate ~njections in the 
Pond-Nuki experimental model of osteoarthritis 
in dogs: I. Biochemical results. Clin Orthopol 
1989;241:278-85. 
28. Schiavanato A, Lini E, Guidolin D. ~tra-art icular  
sodium hyaluronate injections in the Pond- 
Nuki experimental model of osteoarthritis in 
dogs. II. Morphological findings. Clin Orthopol 
1989;241:286-99. 
29. Altman R, Asch E, Block D, et al.: Development 
of criteria for the classification and reporting of 
osteoarthritis. Classification of osteoarthritis of 
the knee. Arthritis Rheum 1986;29:1039-49. 
30. Kellgren JH, Lawrence JS. Radiological assess- 
ment of osteoarthrosis. Ann Rheum Dis 1957;16: 
494-502. 
31. Beguin J, Locker B. Chrondropathie rotulienne. 
In: 2~me Journ~e d'Arthroscopie du genou, Lyon, 
France, 16-17 Sept. 1 Vol. 1993;89-90. 
32. Lequesne MG, Mery C, Samson M, Gerard P. 
Indexes of severity for osteoarthritis of the hip 
and knee. Validation-value in comparison with 
other assessment ests. Scand J Rheumatol 
1987;85(Suppl)65:85~. 
33. Poiraudeau S, Dougados M, Ait-Hadad Hpion-Graff 
J, Ayral X, Listrat V, Courpied JP, Amor B. 
Evaluation of the French version of a quality of 
life scale (AIMS2) in rheumatology patients. Rev 
Rhum Engl Ed, 1993;60:466-72. 
34. Dougados M Gueguen A, Nguyen M, Berdah L, 
Lequesne M, Mazieres B, Vignon E. Radiological 
progression of hip osteoarthritis: Definition, risk 
factors and correlations with clinical status. Ann 
Rheum Dis 1996;55:In Press. 
35. Dacre J, Byrne J, Huskisson EC and the LINK study 
group. Use of a simple scoring system for knee 
osteoarthritis to compare indomethacin, placebo 
and tiaprofenic and in a long-term double blind 
controlled trial in osteoarthritis (abstract). 
Arthritis Rheum 1994;27(Suppl.):S423. 
